Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omega interferon + ribavirin
- Development stage
- Unknown
- Lead developer
- Intarcia Therapeutics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
**Omega interferon + ribavirin** is a combination drug regimen investigated for the treatment of chronic hepatitis C virus (HCV) infection. Omega interferon (human interferon omega-1) is a type I interferon with antiviral, antiproliferative, and immunomodulatory effects. It exerts its action by binding to interferon receptors, inducing transcription of antiviral proteins and modulating the immune response. Ribavirin is a nucleoside analogue with broad-spectrum antiviral activity; it inhibits viral RNA synthesis and induces lethal mutagenesis in RNA viruses. When used together, omega interferon and ribavirin may have synergistic effects, enhancing sustained virologic response in HCV-infected patients. This combination has been studied in clinical trials for its efficacy in hepatitis C[2][1].
- Other names
- human interferon omega-1 + ribavirin
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on omega interferon + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omega interferon + ribavirin.